



Posted 7/9/2019 jrs

CANNON BUILDING
861 SILVER LAKE BLVD., SUITE 203
DOVER, DELAWARE 19904-2467

STATE OF DELAWARE

TELEPHONE: (302) 744-4500
FAX: (302) 739-2711
WEBSITE: DPR.DELAWARE.GOV
EMAIL: customerservice.dpr@delaware.gov

| | |
|-----------------|--|
| MEETING NOTICE: | Prescription Monitoring Program Advisory Committee |
| DATE AND TIME: | 02/12/2019 at 3:00pm |
| PLACE: | Buena Vista Conference Center DuPont Conference Room New Castle, DE 19720 |

Members Present-

Cindy Cunningham, Public Member
Cindy Denemark, Patients' Rights Representative- Department of Health and Social Services
John Goodill, Medical Society of Delaware
Don Keister, Public Member
Julia Lawes, Department of Justice
Kevin Musto, Delaware Pharmacists Society

Members Absent-

Pete Sawyer, Department of Homeland Security

Division Staff and Deputy Attorney General-

Geoff Christ, Director- Office of Controlled Substances
Paul DelPrato, PMP Data Analyst
David Mangler, Director- Division of Professional Regulation
Jason Slavoski, PMP Administrator
Jason Staib, Deputy Attorney General

1. Call to Order

Mr. Keister called the meeting to order at 3:16pm.

1.1. Welcome new Committee Member, Julia Lawes

Committee members introduced themselves to the new Department of Justice Representative, Ms. Lawes.

2. Review of Minutes

Mr. Keister called for a review of the minutes from the previous meeting. Dr. Goodill made a motion to approve minutes. The motion was seconded by Mr. Musto. By unanimous vote, the motion carried.

3. New Business

Mr. Keister called upon Dr. Slavoski to discuss the following:

3.1. Discussion Regarding Updates on PMP Operational Improvements

3.1.1. Prescriber Tools

Dr. Slavoski discussed an enhancement to the PMP that allows users to more easily reset their password using SMS (text message). This had previously been identified as an area of improvement by the 2018 PMP user survey. Dr. Slavoski also discussed the enhancement of the quarterly Prescriber Reports by reducing/eliminating misleading comparisons by using a new Appriss designed comparison algorithm. This enhancement provides a more intuitive comparison between different prescriber types and specialties.

3.1.2. Administrative/Analytic Tools

Dr. Slavoski discussed the new dispenser compliance tool being utilized by his office for the purpose of ensuring that pharmacies that are required to report PMP data to the PMP were doing so as required. He shared that approximately 87% of required pharmacies are uploading PMP data, according to preliminary data obtained during user acceptance testing (UAT).

3.1.3. Interstate Interoperability

Dr. Slavoski discussed PMP Interconnect, the system utilized to allow PMP users to see PMP data from other states that Delaware has entered into an agreement with. He showed a map of the 23 currently connected states and discussed the fact that Delaware would soon be connecting with the United State Department of Defense (DoD) and possibly Florida.

3.1.4. Electronic Health Record Information Systems Integration

Dr. Slavoski discussed PMP Gateway, the system used by the Delaware PMP for the purpose of integrating data/instant access to PMP data into the Electronic Health Record (EHR) or software of health systems and pharmacies. He showed a chart of the 8 health systems and pharmacies currently integrated and discussed that 2,852,036 queries had been completed via the Gateway since July 2018. He showed a chart of the 6 Delaware located facilities and their search statistics to demonstrate the drastic increase of PMP queries accomplished by Gateway integration:

-259,417 queries between August 2018-February 2019 (about 400 active users with roughly 649 searches per user) via Gateway

-352,376 queries during the same time period (about 8,000 active users with roughly 44 searches per user) via PMP Aware.

Mr. Mangler discussed the potential challenge facing the PMP program when grant funding ends in August of 2019. He discussed the fact that the Division of Professional Regulation is entirely license-fee funded, and that the only way to offset increased costs (such as the PMP) is by increasing licensing fees.

4. Executive Session

Ms. Cunningham made a motion to enter Executive Session. The motion was seconded by Ms. Denemark. By unanimous vote, the motion carried. The Committee entered Executive Session at 3:49pm.

4.1. Discussion of New Indicators Available for Specific Referral Criteria

Relating to High Risk Prescribing Pursuant to 29 *Del. C.* §§ 10002(l)(6), 10004(b)(6) and 16 *Del. C.* §§ 4798(v)(1), (w)(2).

Dr. Slavoski introduced New Potential Indicators to consider for Referral Criteria. The Committee voted on and approved the addition of New Indicator(s).

4.2. Approval of Specific Referral Criteria Relating to High Risk Prescribing Pursuant to 29 *Del. C.* §§ 10002(l)(6), 10004(b)(6) and 16 *Del. C.* §§ 4798(v)(1), (w)(2).

The Committee voted on and approved Specific Referral Criteria Relating to High Risk Prescribing.

Mr. Keister made a motion to exit Executive Session. The motion was seconded by Ms. Denemark. By unanimous vote, the Committee exited Executive Session at 4:38pm.

5. Other Business

Ms. Denemark discussed Buspar and certain formulations of hydroxyzine were backordered. She mentioned the importance of this since these drugs are occasionally used as alternatives to certain controlled substances. Ms. Denemark also requested that Dr. Slavoski provide a summary of the impact of HR6 (The SUPPORT Act) on the Delaware PMP at the next meeting.

6. Public Comment

Mr. Keister suggested moving the Public Comment section of the agenda immediately before the Executive Session in case public attendees do not stay until the conclusion of the meeting.

7. Next Meeting

The next meeting will be held on May 21, 2019 at 3:00pm at the Buena Vista Conference Center in the DuPont Room.

8. Adjourn

A motion to adjourn was made by Dr. Goodill and seconded by Mr. Keister. By unanimous vote, the motion carried. The meeting adjourned at 4:43pm.